FIGURE 2.

Change from baseline in MSQoL domain scores^a (A) during the last 4 weeks of the DB period and (B) at 6 months (mITT).^{b a}Score range: 0 to 100; higher scores indicate better HRQoL. ^bAll patients in the OLE of the FOCUS study received fremanezumab 225 mg monthly. DB, double‐blind; EF, emotional function; LSM, least‐squares mean; mITT, modified intent‐to‐treat; MSQoL, Migraine‐Specific Quality of Life; OLE, open‐label extension; RFP, role function—preventive; RFR, role function—restrictive; SE, standard error